Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India.
Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India.
Bioorg Chem. 2018 Apr;77:6-15. doi: 10.1016/j.bioorg.2017.12.037. Epub 2018 Jan 3.
A small library of new benzothiazole clubbed oxadiazole-Mannich bases (M-1 to M-22) were synthesized and characterized by IR, NMR, Mass and Elemental analysis results. Molecular docking studies were done to assess the binding mode and interactions of synthesized hits at binding site of receptor Peroxisome proliferator-activated receptor, PPAR-γ or PPARG (PDB 1FM9). Among the synthesized compounds, nine compounds were selected on the basis of docking score and evaluated for their in vivo anti-diabetic activity using Oral Glucose Tolerance Test (OGTT) in normal rats followed by Streptozotocin (STZ) - induced diabetes. Results indicated that compound M-14 (161.39 ± 4.38) showed the highest reduction of blood glucose level comparable to that of the standard drug glibenclamide (140.29 ± 1.24) in STZ model. Other compounds exhibited moderate to good anti hyperglycaemic activity. ADME studies was done using Molinspiration online software, revealed that all compounds (except M-11) are likely to be orally active as they obeyed Lipinski's rule of five.
一个新的苯并噻唑俱乐部的小图书馆 恶二唑 - 曼尼希碱(M-1 至 M-22)合成并通过红外光谱,核磁共振,质谱和元素分析结果进行了表征。进行了分子对接研究,以评估合成的命中物在过氧化物酶体增殖物激活受体(PPAR-γ 或 PPARG)或 PPARG(PDB 1FM9)受体结合部位的结合模式和相互作用。在所合成的化合物中,基于对接评分选择了九种化合物,并在正常大鼠中进行了口服葡萄糖耐量试验(OGTT)评估其体内抗糖尿病活性,然后用链脲佐菌素(STZ)诱导糖尿病。结果表明,化合物 M-14(161.39±4.38)在 STZ 模型中表现出最高的血糖降低水平,与标准药物格列本脲(140.29±1.24)相当。其他化合物表现出中等至良好的抗高血糖活性。使用 Molinspiration 在线软件进行 ADME 研究表明,除 M-11 外,所有化合物(M-11)都可能具有口服活性,因为它们符合 Lipinski 的五规则。